According to filings with the U.S. Securities and Exchange Commission, Mind Medicine (MindMed) is raising up to $75,000,000.00 in new funding. Sources indicate that as part of senior management Chief Legal Officer, Mark Sullivan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Mind Medicine (MindMed)
MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

To learn more about Mind Medicine (MindMed), visit http://mindmed.co/

Contact:
Mark Sullivan, Chief Legal Officer
212-220-6633

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.